<DOC>
	<DOCNO>NCT02942056</DOCNO>
	<brief_summary>The overall goal proposal establish efficacy cinnamon treatment T2DM . Additional aim assess effect cinnamon cardiovascular risk factor explore novel potential mechanism action lead improved insulin sensitivity . Based previously publish animal human data hypothesize six month treatment Cinnamon cassia supplementation ( 2.25 grams/day ) improve glycemic control cardio-metabolic risk factor . We believe benefit may mediate part improve insulin mediate capillary recruitment skeletal muscle vasodilator lead reduced insulin resistance . We achieve goal completion follow aim : Aim 1 . To demonstrate efficacy , safety , tolerability oral cinnamon use ( 750 mg three time daily ) improve glucose control . The primary outcome determine reduction hemglobin A1c ( HbA1c ) level least 0.5 % compare placebo . Aim 2 . To quantify effect oral cinnamon ( vs. placebo ) cardio-metabolic risk factor , include : fasting level plasma insulin glucose , homeostatic model assessment insulin resistance ( HOMA-IR ) , lipid ( total , VLDL , LDL , HDL cholesterol ; triglyceride ) , free fatty acid , well whole body , abdominal , visceral adiposity measure dual energy x-ray absorptiometry ( DEXA ) imaging . Aim 3 . In mechanistic exploratory aim , potential gastrointesitnal effect assess follow : 3-hour oral glucose tolerance test ( OGTT ) blood sample collect insulin , glucose , C-peptide , glucagon , GLP-1 , GIP perform separately . Additional biochemical marker ( ghrelin , PYY , pro-insulin , apo B , adinopectin ) collect well .</brief_summary>
	<brief_title>The Effect Cinnamon Cassia Diabetes Control Cardiometabolic Risk Factors Adults With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Experimental Design : This Phase 2 study do prospectively conduct two stage . The initial stage general study second stage sub-study . We plan screen 1,000 subject . Our enrollment goal 250 subject total ( 50 subject enrol sub-study 200 subject enrol general study ) . Adults screen Oregon Health &amp; Science University clinic ( cardiology , internal medicine , endocrinology , obstetrics gynecology , family practice ) Epic-based database search research flyer distribution . At OHSU , Research Data Warehouse ( RDW ) use identify potential subject recruitment letter send . Additional advertisement conduct March Wellness medical exercise program . Further outreach advertise do Oregon Association Naturopathic Physicians ( OANP ) website Naturopathic Doctor News &amp; Reviews ( NDNR ) newsletter . We include vulnerable population . We recruit prisoner , child , neonate , and/or adult lack capacity . In event screen failure , data collect screening retain avoid future re-contacting recruitment study . The data handle confidential manner destroyed end enrollment . Inclusion/Exclusion Criteria : Recruited subject meet following criterion : Inclusion Criteria : - Males female age 30-65 year age - Diagnosed Type 2 diabetes HbA1c 6.5-9 % , treat either lifestyle alone metformin - Weight stable 3 month define great 5 % change . Exclusion Criteria : - Pregnancy - Breast feed - Use diabetes treatment metformin within past 3 month - Type 1 diabetes - HbA1c &gt; 9 % less &lt; 6.5 % - Liver disease know diagnosis cirrhosis - Liver Dysfunction AST ALT liver enzymes &gt; 2x upper limit normal - Chronic Kidney Disease glomerular filtration rate &lt; 45 ml/min/1.73m2 - Anemia hematocrit &lt; 30 % - TSH &gt; 5 &lt; 0.4 mIU/L - Coagulopathy , INR &gt; 1.3 - Use warfarin new oral anticoagulant ( dabigatran , rivaroxaban , apixaban ) - Use subcutaneous heparin , enoxaparin , dalteparin - Use class 1 class 3 anti-arrhythmic medication ( disopyramide , procainamide , quinidine , mexilitine , flecanide , propafenone , amiodarone , sotalol , dronedarone , dofetilide ) - Use immunosuppressant ( methotrexate , prednisone , tacrolimus , sirolimus , azathioprine , mycophenolate , cyclosporine ) - Chronic use benzodiazepine ( midazolam , alprazolam , lorezepam , temezepam , diazepam , clonazepam , chlordiazepoxide ) past 3 month - Chronic use medication may affect body weight , glucose lipid metabolism ( e.g. , anti-psychotics , anti-seizure , weight loss med ) past 3 month - Patients celiac sprue gluten sensitive individual - Self-report &gt; 3 alcoholic drink per day - Congestive heart failure ( ejection fraction &lt; 45 % ) - Known hypersensitivity Definity® ultrasound contrast agent ( sub-study ) - Intra-cardiac pulmonary shunt Screening Visit : After receive verbal graphical summary study , subject may opt General Study detail Mechanistic Sub-Study . See . Baseline Visit Week 6 24 Study Visits ( General Study ) : Once subject screen , consent enrol General Study undergo follow test procedure : 1 . For woman child bear potential , urine pregnancy test perform . This must do prior iDEXA scan , do prior randomization . 2 . Complete chemistry panel liver kidney function , fast insulin , complete blood count ( CBC ) , fast lipid panel , urine analysis , iDEXA scan body composition . Subject must fast 8 hour . Any remain blood sample , use study , store repository . 3 . Subjects Actical monitor fit waist wear one week . 4 . 24 hour food recall perform study staff . The recall conduct phone three separate time within 14-21 day baseline 24 week . 5 . Prior baseline visit discharge , subject randomize double blinded fashion 1:1 ratio either 750 mg cinnamon cassia placebo three time daily 24 week . 6 . Pills pick empty bottle return pill count study staff every visit . 7 . After 6 week treatment , subject blood urine test safety monitoring ( liver function test , CBC , urine analysis ) . 8 . After 12 week treatment HbA1c , fast insulin , fast lipid panel drawn interim analysis . Repeat safety profile complete chemistry panel liver kidney function CBC also obtain . Subject must fast 8 hour . 9 . After 24 week therapy , subject return final visit baseline test procedure repeat . ( blood draw , urine test , iDEXA , Actical , food recall ) 10 . Adverse event concomitant medication review . 11 . Baseline visit occur 10 ± 5 day screen visit 12 . All follow-up visit , Weeks 6-24 , do ± 7 day . Baseline Visit Week 6 24 Study Visits ( Sub-Study ) : Those subject consent enrolled Mechanistic Sub-Study undergo follow baseline test procedure : On Day 1 baseline test follow test perform : 1 . For woman child bear potential , urine pregnancy test perform . This must do prior iDEXA scan , do prior randomization . 2 . Complete chemistry panel liver kidney function , fast insulin , CBC , fast lipid panel , HbA1c , urine analysis , iDEXA scan body composition . Any remain blood sample , use study , store repository . On Day 2 baseline testing ( within 1 week Day 1 ) follow test perform : 1 . Oral glucose tolerance test plasma sample obtain prior glucose ingestion GI secretory function analysis . 2 . Subjects Actical activity monitor fit waist wear week . 3 . 24 hour food recall schedule perform study staff . Following completion baseline study , subject randomize double blind fashion 1:1 ratio either 750 mg cinnamon cassia placebo three time daily 24 week . At 6 18 week visit follow test perform : blood draw safety LFTs , CBC , Urinalysis . At 12 week visit follow test procedure perform : 1 . Subjects admit CTRC active metabolite testing . 2 . Subjects blood test safety monitoring ( complete chemistry panel LFTs , CBC , urinalysis ) HbA1c , fast insulin , fast lipid panel drawn interim analysis . After 24 week therapy , subject return final visit baseline test repeat . Methods : All Methods research related inquiry . Dual X-Ray Absorptiometry ( DEXA ) : Body composition ( total lean fat mass skeletal mineral content ) body fat distribution measure trained technician OHSU 's Body Energy Composition Core use GE Healthcare Lunar iDEXA encore software . Pregnancy test performed woman prior total body scan . If result positive , participant withdrawn study refer personal health care provider . OGTT : Following overnight fast , subject IV place antecubital fossa . After least 15 minute rest , three baseline sample obtain subject ingest 75 gm glucose . Blood glucose , insulin , C-peptide , glucagon , GLP-1 , GIP obtain time -15 , -10 , -5 , 0,15 , 30 , 60 , 90 , 120 , 180 minute . Proinsulin measure one baseline sample . Insulin sensitivity estimate use Insulin Sensitivity Index ( 10,000/square root [ fast glucose x fast insulin ] x [ mean glucose x mean insulin OGTT ] ) . 22 Insulin secretion capacity estimate use Insulinogenic Index ( insulinogenic index ( delta area curve [ AUC ] insulin / delta AUC glucose ) . 23 Plasma Chemistries : Total lipid ( total , VLDL , LDL , HDL cholesterol ; triglyceride , apolipoprotein B ) measure OHSU Lipid Lab . Complete chemistry panel , urine analysis , HbA1C , TSH , CBC perform OHSU Core Laboratory . Insulin , glucose , C-peptide , glucagon , GLP-1 , GIP , ghrelin , PYY , pro-insulin , apo B adiponectin measure OCTRI Core Laboratory 24-Hour Diet Recall : A series three 24-hour food recall interview do telephone train OCTRI Bionutrition Unit staff determine nutrient intake . The recall conduct phone three separate time within 14-21 day baseline 6 month . The series three call occur begin intervention phase , last week Intervention ( 6 month ) ensure extent possible diet habit maintain . The recall unannounced unscheduled participant unlikely change normal eating habit . All interviewer complete train program meet qualification standard establish OCTRI Bionutrition Unit base Nutrition Data System Research ( NDSR ) . NDSR computer base software application develop University Minnesota Nutrition Coordinating Center ( NCC ) facilitate collection recall standardize fashion [ 19 ] . Dietary intake data gather interview govern multiple-pass interview approach [ 20 ] . Four distinct pass provide multiple opportunity participant recall food intake . The first pas involve obtain participant listing food beverage consume previous 24 hour . This listing review participant completeness correctness ( second pas ) . The interviewer collect detailed information report food beverage , include amount consume method preparation ( third pas ) . Finally , detailed information review completeness correctness ( fourth pas ) . Activity Monitors : Physical activity monitor use Actical accelerometer ( Mini Mitter Co. , Inc. , Bend , Oregon ) . The Actical activity monitoring device utilizes multidirectional accelerometer monitor occurrence intensity motion . The Actical device measure 3 cm 3 cm , weigh 17.0 gram , securely attach waistband place around waist . The device worn collect data 42 day . Data upload download use ActiReader . Data include Daily Active Energy Expenditure Total Daily Energy Expenditure . Actical 's activity count data convert minute-by-minute energy expenditure . This used calculate daily caloric expenditure . Physical activity monitor seven day period baseline , 6 month time point post randomization . Plasma Cinnamon Metabolite Identification : Plasma metabolites constitute active metabolite form cinnamon test steady state therapy 3 month time point . Subjects instructed take morning dose study drug 2 hour ( +/- 30 minute ) schedule study visit . They admit clinical trial unit morning , possible . Blood drawn safety analysis well active plasma metabolite . Lunch provide . A second blood draw active metabolite obtain 6 hour ( +/- 30 minute ) first blood draw prior next cinnamon dose test difference metabolites 8 2pm . All blood sample active metabolite batch tested end trial maintain blinding study . Metabolites find significantly different ( p &lt; 0.05 ) experimental group identify search in-house library contains &gt; 600 metabolite ( Mass Spectrometry Metabolite Library Standards , IROA Technologies , LLC ) &gt; 100 phytochemical ) , LipidView database contain &gt; 25,000 lipid . When metabolites interest absent in-house library metabolite LipidView database , perform online database search ( METLIN ; http : //metlin.scripps.edu , HMDB ; http : //www.hmdb.ca/ , MassBank ; http : //www.massbank.jp/ ? lang=en ) use accurate mass . When available , database MS/MS spectrum use confirm identity metabolite . If metabolite interest absent database , PeakView software ( AB SCIEX ) use create potential list molecular formula match measure m/z value ( within 15 ppm error ) , fragmentation pattern , isotopic distribution ( within 20 % error ) . For many metabolite identify , synthetic standard purchase confirm method specific MS/MS spectrum , retention time , experimental m/z value , isotopic distribution .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Males female age 3065 year age Diagnosed Type 2 diabetes HbA1c 6.59 % , treat either lifestyle alone metformin Weight stable 3 month define great 5 % change . Pregnancy Breast feeding Use diabetes treatment metformin within past 3 month Type 1 diabetes HbA1c &gt; 9 % less &lt; 6.5 % Liver disease know diagnosis cirrhosis Liver Dysfunction AST ALT liver enzymes &gt; 2x upper limit normal Chronic Kidney Disease glomerular filtration rate &lt; 45 ml/min/1.73m2 Anemia hematocrit &lt; 30 % TSH &gt; 5 &lt; 0.4 mIU/L Coagulopathy , INR &gt; 1.3 Use warfarin new oral anticoagulant ( dabigatran , rivaroxaban , apixaban ) Use subcutaneous heparin , enoxaparin , dalteparin Use class 1 class 3 antiarrhythmic medication ( disopyramide , procainamide , quinidine , mexilitine , flecanide , propafenone , amiodarone , sotalol , dronedarone , dofetilide ) Use immunosuppressant ( methotrexate , prednisone , tacrolimus , sirolimus , azathioprine , mycophenolate , cyclosporine ) Chronic use benzodiazepine ( midazolam , alprazolam , lorezepam , temezepam , diazepam , clonazepam , chlordiazepoxide ) past 3 month Chronic use medication may affect body weight , glucose lipid metabolism ( e.g. , antipsychotic , antiseizure , weight loss med ) past 3 month Patients celiac sprue gluten sensitive individual Selfreport &gt; 3 alcoholic drink per day Congestive heart failure ( ejection fraction &lt; 45 % )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>